“Sales revenues in the first nine months were up on a year-on-year basis in most markets in both HUF and EUR terms, fueled by growth in the specialty portfolio, in particular higher Vraylar® and Evra® royalties. This broad-based strength in revenue performance was translated into a solid bottomline also ex-Vraylar®, despite higher spending on R&D […]


















